.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Modern radiotherapy faces significant challenges when optimizing VMAT breast cancer planning for patients with extensive lymph node involvement. A recent international study led by the European Federation of Organisations for Medical Physics surveyed 25 participants to identify effective strategies. Consequently, this investigation provides valuable insights into clinical practices across various institutions. By examining diverse planning routines, the research highlights the need for standardized protocols in managing these complex scenarios.
The study results revealed a wide variation in beam geometry and dose constraints. For instance, mean heart doses ranged significantly from 1.5 to 9.5 Gy. Additionally, ipsilateral lung doses varied between 12.0 and 17.3 Gy. These differences underscore how institutional priorities influence the balance between target coverage and organ sparing. Furthermore, the survey covered critical topics such as simultaneous integrated boost (SIB) prescriptions and organs at risk (OAR) prioritization.
Researchers presented five specific planning strategies that achieved high target coverage while maintaining the lowest doses to critical organs. Specifically, these methods successfully optimized the dose to the breast and lymph node volumes without compromising the safety of the heart and lungs. Because clinical goals often conflict, these proven strategies offer a roadmap for planners. Therefore, adopting these techniques can improve the consistency and quality of radiation therapy for breast cancer patients worldwide.
The main challenge involves achieving adequate dose coverage for both the breast and regional lymph nodes while minimizing radiation exposure to the heart and lungs. Standardizing these goals across different institutions remains difficult.
The study found that mean heart doses varied from 1.5 Gy to 9.5 Gy, reflecting significant differences in institutional priorities and planning techniques.
An SIB is a technique where clinicians deliver a higher dose of radiation to the tumor site while the rest of the breast receives a standard dose, all within the same treatment session.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
An international study explores VMAT treatment planning for breast cancer with lymph node involvement. It identifies five effective strategies to balance high target coverage with the protection of organs at risk like the heart and lungs, addressing wide variations in clinical practice.
4 months ago
Novel glucose-responsive mPEG-PSA nanocarriers deliver insulin aspart on demand, achieving dual postprandial and basal glycemic control without hypoglycemia in diabetic models. This biomaterial breakthrough offers promising clinical implications for physiologic diabetes management.
Today
A novel folate-conjugated tecto-dendrimer nanoplatform successfully delivers siRNA to achieve targeted HK2 silencing, disrupting ovarian cancer glycolysis and suppressing lactate output.
Today
A comparative non-contact study reveals that high-power radiofrequency delivery with the QDOT MICRO catheter induces an artifactual contact force rise. Electrophysiologists must understand this power-dependent thermal and electrical phenomenon to avoid inadvertent catheter withdrawal and ineffective ablation.
Today
A novel proof-of-concept study presents a six-degree-of-freedom articulated manikin neck equipped with linear potentiometers. The system provides real-time kinematic motion feedback during cervical immobilisation, delivering sub-degree tracking accuracy to improve pre-hospital trauma training and patient safety.
Today
A retrospective comparative cohort study evaluated genitourinary safety in HFpEF between dapagliflozin and empagliflozin over six months. Rates of symptomatic UTI and asymptomatic bacteriuria showed no statistically significant differences, supporting comparable safety profiles across both SGLT2 inhibitors.
Today
